Shares of Achillion Pharmaceuticals (ACHN) have experienced an impressive 95% increase over the past five days due to encouraging Phase 1 data reported for complement factor D inhibitor candidate ACH-5228. Since the beginning of 2019, the stock has risen by over 190%.
After such a high degree of appreciation, it's easy for investors on the sidelines to assume the train has left without them. However, I've often discussed the importance of avoiding such bias (writing off a stock simply because it's taken off without you).
As an example, one of our model account